Evotec stock trades at EUR 2.80, 2.6 percent above its 52-week low

Published on 10/08/2026 at 17:57 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Evotec stock stood at EUR 2.80 on October 8, 2026 versus EUR 2.91. The quote fell 3.8 percent and sat above EUR 2.73.

Key points in brief

Evotec stock was at EUR 2.80 at Lang & Schwarz on October 8, 2026 at 5:50 p.m. CEST, down 3.78 percent versus EUR 2.91.
The price stood 2.56 percent above the EUR 2.73 52-week low and remained below the EUR 7.70 high.
Second-quarter 2026 revenue was EUR 143.50 million, while adjusted EBITDA was a EUR 42.70 million loss in the first half of 2026.

Trading-Floor mit großen Bildschirmen, Aktiencharts und dem Index-Kürzel MDAX — Börsen-Editorial mit Handelssaal und MDAX-Charts illustriert das Marktumfeld von Evotec SE, ISIN DE0005664809, im Biotech-Sektor, Illustration mit AI erstellt.

Evotec stock stood at EUR 2.80 at Lang & Schwarz on October 8, 2026 at 5:50 p.m. CEST, down 3.78 percent versus the EUR 2.91 prior close. The price was 2.56 percent above the EUR 2.73 52-week low, keeping the market report centered on range placement rather than a new corporate event.

Price remains near yearly low

The Lang & Schwarz bid was EUR 2.79 and the ask was EUR 2.82 at the same after-hours timestamp. The spread of EUR 0.03 was small in absolute terms, but the daily decline left the stock close to its lowest quoted level of the past year.

The 52-week range extended from EUR 2.73 to EUR 7.70 on October 8, 2026, according to Börse Express. At EUR 2.80, the stock was 63.64 percent below that high, while only EUR 0.07 separated it from the low.

Second-quarter figures remain weak

Evotec reported EUR 143.50 million in revenue for the second quarter of 2026, down 16.20 percent from EUR 171.20 million a year earlier. The first half of 2026 produced EUR 300.10 million in revenue, a year-over-year decline of 19.20 percent, according to Nadiralpha.

Adjusted EBITDA was a EUR 42.70 million loss in the first half of 2026, compared with a EUR 1.90 million loss in the first half of 2025. Second-quarter operating income reached a EUR 113.30 million loss, including EUR 98.90 million in reorganization costs and asset impairments plus a separate EUR 42.30 million impairment on a Hamburg laboratory building.

Comparison with peers

Evotec: minus 3.78 percent, P/E minus 2.53, market capitalization USD 548.8 million

Sartorius Stedim Biotech (USD): minus 4.26 percent, P/E 68.87, market capitalization USD 226.2 billion

Qiagen (USD): minus 1.00 percent, P/E 22.75, market capitalization USD 9.1 billion

Analyst target remains above price

Börse Express reported that Berenberg maintained a Hold rating and a EUR 3.60 price target. The target lies 28.57 percent above the Lang & Schwarz price, while the portal listed a 12-month consensus target of EUR 3.80 from four houses.

Evotec's latest reported guidance for fiscal year 2026 calls for revenue of EUR 570 million to EUR 610 million and adjusted EBITDA of a EUR 70 million to EUR 105 million loss. The figures frame the current share price against a business outlook that remains materially below the earlier revenue range of EUR 700 million to EUR 780 million.